封面
市場調查報告書
商品編碼
1347587

癌症疫苗市場:2023-2028 年全球行業趨勢、佔有率、規模、成長、機遇和預測

Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

市場概況:

2022年全球癌症疫苗市場規模達到61億美元。展望未來,IMARC Group預計到2028年市場規模將達到121億美元,2023-2028年年複合成長率(CAGR)為11.61%。

癌症是由於體內異常細胞不受控制地生長而引起的惡性腫瘤。它可以通過使用各種藥物和疫苗來治療。其中,疫苗大致分為預防性疫苗和治療性疫苗。預防性癌症疫苗用於消除由腫瘤病毒引起的癌症並預防人類乳突病毒 (HPV),而治療性疫苗則通過使用腫瘤抗原幫助刺激個體適應性免疫系統。目前,商業上的癌症疫苗有多種類型,例如抗原、樹突狀細胞和抗獨特型。

癌症疫苗市場趨勢:

癌症患病率不斷上升,特別是由於菸草產品消費的增加和生活方式的不斷變化,目前正在推動癌症疫苗市場的成長。據此,一些國家的政府機構為引入新型癌症疫苗而採取的有利舉措,以及在病毒重組癌症疫苗領域的大量資金,進一步促進了這些疫苗在醫療保健領域的廣泛採用。與此相一致的是,廣泛使用美國食品和藥物管理局(US FDA)批准的疫苗,包括人類乳突病毒疫苗(HPV)和乙型肝炎疫苗(HBV)來降低某些類型癌症(例如肝癌)的風險,正在為市場成長做出貢獻。該市場還受到專注於開發有效和特定癌症治療方法的快速技術進步的顯著推動。其他因素,例如醫療基礎設施的改善、易患包括癌症在內的各種慢性疾病的老年人口不斷增加,以及消費者對症狀和可用治療方案的認知不斷增強,正在為全球市場進一步創造積極的前景。

本報告回答的關鍵問題:

  • 迄今為止,全球癌症疫苗市場表現如何,未來幾年將如何表現?
  • COVID-19 對全球癌症疫苗市場有何影響?
  • 主要區域市場有哪些?
  • 根據類型分類市場是怎樣的?
  • 基於技術的市場細分是什麼?
  • 根據指示,市場的細分是什麼?
  • 基於最終用戶的市場細分是什麼?
  • 行業價值鏈的各個階段是什麼?
  • 該行業的關鍵促進因素和挑戰是什麼?
  • 全球癌症疫苗市場的結構如何?誰是主要參與者?
  • 行業競爭程度如何?

目錄

第一章:前言

第 2 章:範圍和方法

  • 研究目的
  • 利益相關者
  • 數據源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章:執行摘要

第 4 章:簡介

  • 概述
  • 主要行業趨勢

第 5 章:全球癌症疫苗市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章:按類型分類的市場細分

  • 預防癌症疫苗
    • 市場走向
    • 市場預測
  • 治療性癌症疫苗
    • 市場走向
    • 市場預測

第 7 章:按技術分類的市場

  • 樹突狀細胞癌症疫苗
    • 市場走向
    • 市場預測
  • 重組癌症疫苗
    • 市場走向
    • 市場預測
  • 抗原/佐劑癌症疫苗
    • 市場走向
    • 市場預測
  • 病毒載體和 DNA 癌症疫苗
    • 市場走向
    • 市場預測
  • 全細胞癌症疫苗
    • 市場走向
    • 市場預測

第 8 章:按跡象分類的市場

  • 宮頸癌
    • 市場走向
    • 市場預測
  • 前列腺癌
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章:最終用戶的市場細分

  • 兒科
    • 市場走向
    • 市場預測
  • 成年人
    • 市場走向
    • 市場預測

第 10 章:按地區分類的市場細分

  • 北美
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳大利亞
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 11 章:SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章:價值鏈分析

第 13 章:波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章:價格分析

第15章:競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Anixa Biosciences Inc.
    • Dendreon Pharmaceuticals LLC
    • Dynavax Technologies Corporation
    • GSK plc
    • Merck & Co. Inc.
    • Moderna Inc.
    • OSE Immunotherapeutics
    • Providence Therapeutics
    • Sanofi SA
    • UbiVac Inc.
    • Vaccitech plc
Product Code: SR112023A5901

Market Overview:

The global cancer vaccines market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2028, exhibiting a growth rate (CAGR) of 11.61% during 2023-2028.

Cancer is a malignant tumor caused by the uncontrollable growth of abnormal cells in the body. It can be treated through the use of various medications and vaccines. Between these, vaccines are broadly categorized into preventive and therapeutic. Preventive cancer vaccines are deployed for eliminating cancer caused by oncovirus and protecting from human papillomavirus (HPV), whereas therapeutic vaccines aid in stimulating the individual adaptive immune systems by using tumor antigens. At present, cancer vaccines are commercially available in varying types, such as antigen, dendritic cell, and anti-idiotype.

Cancer Vaccines Market Trends:

The increasing prevalence of cancer, especially due to the rising consumption of tobacco-based products and evolving lifestyles is currently driving the cancer vaccines market growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel cancer vaccines, along with extensive fundings in the field of viral recombinant cancer vaccines are further facilitating the widespread adoption of these vaccines in the healthcare sector. In line with this, the extensive utilization of United States Food and Drug Administration (US FDA) approved vaccines, including human papillomavirus vaccine (HPV) and hepatitis B vaccine (HBV) to reduce the risk of certain types of cancer, such as liver cancer, is contributing to the market growth. The market is also significantly driven by rapid technological advancements focusing on the development of effective and specific cancer treatments. Other factors, such as improving healthcare infrastructure, rising geriatric population, who are susceptible to various chronic ailments, including cancer, and growing consumer awareness regarding the symptoms and the available treatment options, are creating a positive outlook for the market further across the globe.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer vaccines market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, technology, indication and end user.

Breakup by Type:

Preventive Cancer Vaccines

Therapeutic Cancer Vaccines

Breakup by Technology:

Dendritic Cells Cancer Vaccines

Recombinant Cancer Vaccines

Antigen/Adjuvant Cancer Vaccines

Viral Vector and DNA Cancer Vaccines

Whole-cell Cancer Vaccines

Breakup by Indication:

Cervical Cancer

Prostate Cancer

Others

Breakup by End User:

Pediatrics

Adults

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.

Key Questions Answered in This Report:

  • How has the global cancer vaccines market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global cancer vaccines market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer vaccines market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Preventive Cancer Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Dendritic Cells Cancer Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Recombinant Cancer Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antigen/Adjuvant Cancer Vaccines
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Viral Vector and DNA Cancer Vaccines
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Whole-cell Cancer Vaccines
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cervical Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Prostate Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Anixa Biosciences Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Dendreon Pharmaceuticals LLC
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Dynavax Technologies Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 GSK plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Merck & Co. Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Moderna Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 OSE Immunotherapeutics
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Providence Therapeutics
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 UbiVac Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Vaccitech plc
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials

List of Figures

  • Figure 1: Global: Cancer Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Vaccines Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Cancer Vaccines Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Cancer Vaccines Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Cancer Vaccines Market: Breakup by Technology (in %), 2022
  • Figure 6: Global: Cancer Vaccines Market: Breakup by Indication (in %), 2022
  • Figure 7: Global: Cancer Vaccines Market: Breakup by End User (in %), 2022
  • Figure 8: Global: Cancer Vaccines Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Cancer Vaccines (Cervical Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Cancer Vaccines (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Cancer Vaccines (Prostate Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Cancer Vaccines (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Cancer Vaccines (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Cancer Vaccines (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Cancer Vaccines (Pediatrics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Cancer Vaccines (Pediatrics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Cancer Vaccines (Adults) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Cancer Vaccines (Adults) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: North America: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: North America: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: United States: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: United States: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Canada: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Canada: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Asia-Pacific: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Asia-Pacific: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: China: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: China: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Japan: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Japan: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: India: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: India: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: South Korea: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: South Korea: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Australia: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Australia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Indonesia: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Indonesia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Europe: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Europe: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Germany: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Germany: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: France: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: France: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: United Kingdom: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: United Kingdom: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Italy: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Italy: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Spain: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Spain: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Russia: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Russia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Latin America: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Latin America: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Brazil: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Brazil: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Mexico: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Mexico: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Middle East and Africa: Cancer Vaccines Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Middle East and Africa: Cancer Vaccines Market: Breakup by Country (in %), 2022
  • Figure 81: Middle East and Africa: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Global: Cancer Vaccines Industry: SWOT Analysis
  • Figure 83: Global: Cancer Vaccines Industry: Value Chain Analysis
  • Figure 84: Global: Cancer Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Vaccines Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Cancer Vaccines Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Cancer Vaccines Market Forecast: Breakup by Technology (in Million US$), 2023-2028
  • Table 4: Global: Cancer Vaccines Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 5: Global: Cancer Vaccines Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 6: Global: Cancer Vaccines Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Cancer Vaccines Market: Competitive Structure
  • Table 8: Global: Cancer Vaccines Market: Key Players